Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) with the trade name Aptivus®. It is used in combination therapy to treat HIV infection.

Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors. Resistance to tipranavir itself seems to require multiple mutations. Tipranavir is given in combination with Ritonavir 200 mg twice daily.

Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005. Nelfinavir is the only other FDA approved nonpeptidic protease inhibitor. Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, it tends to have more side effects.

References

Antivirals

Tipranavir | ทิปรานาเวียร์